Navigation Links
Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Date:1/8/2008

tment period. The primary efficacy endpoint of the trial will be the increase from baseline in spontaneous bowel movements per week (SBMs per week). Additional endpoints include monitoring of other symptoms of OBD, which will include the Patient Assessment of Constipation Symptoms (PAC-SYM) outcomes tool, and other quality of life measures. Maintenance of opioid analgesic effect will be assessed by measuring changes from baseline in mean daily opioid requirements and daily pain scores. Safety and tolerability will be assessed and pharmacokinetics of the drug will be evaluated. The trial will be conducted in approximately 50 centers in North America and Europe.

About NKTR-118

NKTR-118 is an oral drug that combines Nektar's advanced small molecule PEGylation technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. In preclinical studies, Nektar's PEGylation technology has been shown to reduce penetration of drugs across the blood-brain barrier, an important potential advance for NKTR-118 and possibly many other small molecule therapies.

The peripheral opioid antagonist NKTR-118 targets opioid receptors within the enteric nervous system, which mediate OBD, a symptom complex resulting from opioid use that encompasses constipation, bloating, abdominal cramping, and gastroesophageal reflux. Constipation is the hallmark of this syndrome, and is generally its most prominent component. Currently, there are no specific drugs approved or specifically indicated to treat OBD or OIC. NKTR-118 has been studied in two Phase 1 trials evaluating the safety, tolerability and pharmacokinetics of single and repeated dose administration of the drug.

In a proof-of-principle Phase 1 trial, single oral doses of NKTR-118 antagonized morphine-induced delay in gastrointestinal transit time demonstrating the potential of the drug to relieve constipation caused by opioid treatment. This effect was seen to increase in a dose-dependent fas
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
7. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
8. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
9. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
10. Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
11. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Novastem, a leader in regenerative medicine, ... its study for ischemic stroke at Clinica Santa ... strokes account for 87 percent of all stroke ... the study, entitled "Internal Research Protocol in Combination ... Cells and Intrathecal Administration of Neural Stem Cells ...
(Date:12/24/2014)... Pa. , Dec. 24, 2014  Commonwealth Cornerstone Group ... Markets Tax Credits transaction on Tuesday to help fund the ... Network (PHN) in Sharon . ... in Pennsylvania . It is the largest ... with more than 150 people on staff. Currently, ...
(Date:12/24/2014)... 24, 2014 Kinex Pharmaceuticals announced today that ... Roswell Park Cancer Institute. KX2-361 (KX02), a ... has shown potent inhibitory activity against a broad panel ... resistant to Temozolomide (T98G), the most widely used chemotherapy ... brain tumor mouse model, KX2-361 consistently clears brain tumors ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... announces that a new market research report is ... Cardiac Defibrillators Industry http://www.reportlinker.com/p098394/Global-Cardiac-Defibrillators-Industry.html ... markets for Cardiac Defibrillators in Units and US$ ... analyzed by the following segments - Implantable/Internal Cardiac ...
... 24, 2011 Reportlinker.com announces that a new ... Global ECG Telemetry Devices Industry ... This report analyzes the worldwide markets for ... following Product Segments: Patient Digital Transmitters, Electrical Leads, ...
Cached Medicine Technology:Reportlinker Adds Global Cardiac Defibrillators Industry 2Reportlinker Adds Global ECG Telemetry Devices Industry 2
(Date:12/26/2014)... December 26, 2014 The Biofeedback Federation ... March 24-28, 2015 in Rome, Italy and is hosted ... workshops on a wide variety of topics ... as peak performance training in athletes. The scientific program ... world. , Biofeedback monitoring allows clients to see what ...
(Date:12/26/2014)... PA (PRWEB) December 26, 2014 Pentec ... Work in the state of Pennsylvania for 2014. The ... first statewide programs of its kind in the country. ... Foundation, the Pennsylvania Department of Community and Economic Development, ... Resource Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 This ... state of the global Sterilizers industry with a focus ... on the market status of the Sterilizers manufacturers and ... companies and individuals interested in the industry. This report ... definition, applications and manufacturing technology. In this part, the ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue ... reports. According to an Order issued in the U.S. ... the Court will convene an open conference on January ... and United States Courthouse in West Palm Beach, Florida. ...
(Date:12/25/2014)... The short film “Color of Honor” by young director/producer ... true 9/11 hero, Welles Remy Crowther. It has been chosen ... of Nuremberg International Short Film Festival and the 8th International ... and director Luciana Lagana plays the mother of the ... Gregory Graham - Graham plays a heroic policeman ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... Social Media Guru Mashable.com Cites Organizations Using Social Media for ... July 1 The Oral Cancer Foundation was recently praised ... discussing non-profit organizations that are effectively using Internet-based social media ... focused exclusively on Web 2.0 and social media such as ...
... Zufall Health Center, a federally qualified health center operating ... eco-friendly mobile medical unit. , , The Highlands ... to low-income, mostly uninsured residents of Hunterdon, Warren and ... at a ribbon cutting ceremony in Flemington. , ...
... transplantation offers a good chance for survival for patients ... factors are associated with worse outcomes. Patients who are ... children whose liver failure was caused by antiepileptic drugs ... are in the July issue of Liver Transplantation ...
... TeamHealth Demonstrates Ongoing Commitment to Patient Care through Patient ... 1 TeamHealth announced today that it has been ... On July 1, its patient safety organization -- the ... the Agency for Healthcare Research and Quality (AHRQ), the ...
... ... vivid personal stories about Internet dating and end-of-life dilemmas. Some stories will be used for ... Kenner. , ... 1, 2009 -- Kayce Freed Jennings, the wife of late ABC newsman Peter Jennings, and Marc ...
... what remains unclear , WEDNESDAY, July 1 (HealthDay News) -- ... more common in recent years, a new Mayo Clinic study ... issue of Gastroenterology , the disease is four times ... 1950s. In addition, the researchers found that the death rate ...
Cached Medicine News:Health News:Oral Cancer Foundation Praised for Its Social Media Efforts 2Health News:Nation's First Eco-Friendly Mobile Health Van Launched by New Jersey Non-Profit Health Center 2Health News:Nation's First Eco-Friendly Mobile Health Van Launched by New Jersey Non-Profit Health Center 3Health News:Study examines liver transplantation after drug induced acute liver failure 2Health News:Study examines liver transplantation after drug induced acute liver failure 3Health News:TeamHealth Recognized by National Quality Agency 2Health News:TeamHealth Recognized by National Quality Agency 3Health News:First-Person Stories Gathered on Web Shape New Nonfiction TV Series from Veteran Producers 2Health News:First-Person Stories Gathered on Web Shape New Nonfiction TV Series from Veteran Producers 3Health News:First-Person Stories Gathered on Web Shape New Nonfiction TV Series from Veteran Producers 4Health News:Celiac Disease Making Inroads in U.S. 2
...
... provide you with an alternative method for ... proven design as Ad-Techs Spencer Probe Depth ... an introducing needle instead of a stylet. ... 3 to 6 platinum recording contacts, 5.0 ...
... Spencer Probe Depth Electrodes offers you superior ... main body structure which uses a special, ... become more flexible as it reaches body ... feature a small 1.0 mm diameter size. ...
... Miditron Junior II is ... analyser for standardised reflectance ... and software features allow ... performance and convenience to ...
Medicine Products: